Table 1. Factors explored as covariates to be associated with physician decisions to assign either an ARSI or a taxane in patients with mCRPC*.

Number of prior systemic therapies in metastatic setting

Prior treatment with ARSI
Prostate-specific antigen levels
Patient’s age
Presence of liver metastases
High alkaline phosphatase levels
Presence of bone metastases
Presence of lung metastases
Presence of lymph node metastases
Low albumin levels
High lactate dehydrogenase levels
Low hemoglobin levels

*, factors are here ranked according to the importance of their influence on the choice of taxane treatment (odds for taxane use).